These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33642060)

  • 21. Subthreshold Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy.
    Scholz P; Ersoy L; Boon CJ; Fauser S
    Ophthalmologica; 2015; 234(4):189-94. PubMed ID: 26406874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses.
    van Dijk EHC; Feenstra HMA; Bjerager J; Grauslund J; Boon CJF; Subhi Y
    Acta Ophthalmol; 2023 Mar; 101(2):140-159. PubMed ID: 36178171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Reibaldi M; Cardascia N; Longo A; Furino C; Avitabile T; Faro S; Sanfilippo M; Russo A; Uva MG; Munno F; Cannemi V; Zagari M; Boscia F
    Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China.
    Zhao T; Li J; Wang Y; Guo X; Sun Y
    Ann Med; 2023 Dec; 55(1):2227424. PubMed ID: 37382371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy.
    Pichai J; Vanchalerm B; Mansing R
    BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: A meta-analysis.
    Li X; Long H; Hu Q
    Photodiagnosis Photodyn Ther; 2022 Sep; 39():102931. PubMed ID: 35636735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study.
    Pinto C; Sousa K; Oliveira E; Mendonça L; Gentil R; Queirós L; Falcão M
    Semin Ophthalmol; 2022 Feb; 37(2):153-157. PubMed ID: 34027797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.
    Altınel MG; Acikalin B; Gunes H; Demir G
    Lasers Med Sci; 2021 Sep; 36(7):1505-1514. PubMed ID: 33409750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.